Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Menopause has also been suggested as a factor that increases the probability of maintaining normoprolactinemia after dopamine agonist therapy is stopped.18 Unless there is evidence of growth of a prolactinoma or related symptoms, such as headache, there is no indication to continue dopamine agonist therapy after menopause.18 There are no significant differences in age, sex, initial dopamine agonist dose or length of treatment between those with continued normoprolactinemia and those with recurrence of hyperprolactinemia.18 We suggest that the dopamine agonist dose be decreased after 2 or 3 years of normal prolactin levels and that therapy be stopped if the prolactin levels remain unchanged after 1 year at the reduced dose
Administered through a subcutaneous injection every week, Zepbound aids in weight loss by influencing the bodys response to food intake
SC Injection : Technique : Pinch the skin gently to lift the subcutaneous tissue away from the muscle
If the urge feels more like a psychological pull than a physical stomach sensation, the medication may be working while behavioral patterns remain
Journal of the Academy of Public Health
[PMID: 25709639] PubMed record related to this compound for laboratory literature review
